Logo

ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives MHLW's Approval to Treat HIV 1 Infection

Share this

ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives MHLW's Approval to Treat HIV 1 Infection

Shots:

  • The approval is based on GEMINI 1 & 2 studies assessing dual drug regimen (dolutegravir 50 mg/lamivudine 300 mg) vs dolutegravir + two NRTIs [tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)] in 1400 patients with HIV-1 infection aged> 12yrs. weighing at least 40kg
  •  The GEMINI 1 & 2 study results demonstrated non-inferior efficacy based on plasma HIV-1 RNA <50copies/ml @48wks.- safety is consistent with product labeling  
  • Dovato (qd) is a single-pill- 2-drug regimen to treat naïve HIV infection- combining an integrase inhibitor (INI) with the nucleoside reverse transcriptase inhibitor (NRTI) and is an authorized therapy in the EU for HIV-1 infection

Click here ­to­ read full press release/ article | Ref: GSK | Image: ViiV Healthcare


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions